Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interactions between single-stranded DNA binding protein and oligonucleotide analogs with different backbone

X Cheng1, R K DeLong, E Wickstrom

  • 1Department of Pharmacology, University of North Carolina, Chapel Hill 27599, USA.

Journal of Molecular Recognition : JMR
|March 1, 1997
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IGF1R-Targeted Delivery of a Bridged Nucleic Acid Oligonucleotide-Peptide Conjugate for MicroRNA-21 Inhibition in Triple-Negative Breast Cancer.

bioRxiv : the preprint server for biology·2025
Same author

Translating Nanomedicine to Comparative Oncology-the Case for Combining Zinc Oxide Nanomaterials with Nucleic Acid Therapeutic and Protein Delivery for Treating Metastatic Cancer.

The Journal of pharmacology and experimental therapeutics·2019
Same author

Intracellular Trafficking and Endosomal Release of Oligonucleotides: What We Know and What We Don't.

Nucleic acid therapeutics·2018
Same author

RGD Conjugated Dendritic Polylysine for Cellular Delivery of Antisense Oligonucleotide.

Journal of nanoscience and nanotechnology·2018
Same author

Recent Developments in Oligonucleotide Based Therapeutics. Preface.

Advanced drug delivery reviews·2015
Same author

Trophoblast expression of the minor histocompatibility antigen HA-1 is regulated by oxygen and is increased in placentas from preeclamptic women.

Placenta·2015

Antisense oligonucleotides with modified backbones show varying binding affinities to single-strand binding protein (SSB). Phosphorothioate (PS) and phosphorodithioate (PS2) backbones enhance binding, while methylphosphonate (MP) does not, impacting biological activity.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Oligonucleotide Chemistry

Background:

  • Chemical modification of oligonucleotide backbones is crucial for enhancing antisense effects.
  • Altered backbone chemistry can influence interactions with cellular proteins, affecting biological activity.
  • Single-strand binding protein (SSB) plays a vital role in DNA repair and replication.

Purpose of the Study:

  • To investigate the binding affinity of oligonucleotides with different backbone chemistries to SSB.
  • To determine how backbone modifications impact oligonucleotide-SSB interactions.
  • To assess the role of backbone chemistry in the biological efficacy of antisense oligonucleotides.

Main Methods:

  • Synthesized oligonucleotides with identical sequences but varied internucleoside linkages: phosphodiester (PO), phosphorothioate (PS), phosphorodithioate (PS2), and methylphosphonate (MP).

Related Experiment Videos

  • Assessed the binding affinity of these modified oligonucleotides to SSB using biophysical methods.
  • Evaluated the influence of oligonucleotide length and sequence on SSB binding.

    • Main Results:

    • Phosphorothioate (PS) and phosphorodithioate (PS2) oligonucleotides exhibited higher binding affinity to SSB compared to phosphodiester (PO) oligonucleotides.
    • Methylphosphonate (MP) oligonucleotides showed negligible binding to SSB at tested concentrations.
    • Oligonucleotide length significantly influenced SSB binding, whereas sequence was a less critical factor.

    Conclusions:

    • Oligonucleotide backbone chemistry is a critical determinant of binding affinity to essential cellular proteins like SSB.
    • These findings highlight the importance of considering backbone modifications when designing antisense oligonucleotides for therapeutic applications.
    • Understanding these interactions can optimize the design of antisense agents for improved biological outcomes.